A phase 1 study is ongoing using CD276 chimeric antigen receptor autologous T-cell therapy for pediatric patients with solid tumors (including ACC), but otherwise, there is no clinical data on CD276 inhibition in ACC. This evidence concerns the gene CD276 and adrenal cortex carcinoma.